With unprecedented scientific advances over the last decade in genome sequencing, we now have an opportunity to make genomics testing a standard practice in cancer care. The valuable genetic information that genome sequencing can deliver will alter the future of cancer care from the current singular treatment approach toward tailoring treatment to more precisely match a patient’s genomic profile.
The National Access Project for Cancer Testing, managed by the Personalized Medicine Initiative with testing provided by Contextual Genomics, is designed to drive and facilitate a paradigm shift toward personalized cancer care in which medication selection will be selected on the basis of a patient’s genetic tumor profile. Physicians, patients, pharmaceutical companies, payers, and healthcare systems are advocating for personalized medicine because there’s no question of the benefits it will bring to healthcare. What we will gain from this tailored treatment approach is better health outcomes, reduced adverse drug reactions, patient empowerment, and a major cost-savings on health care systems.
For the rest of the story, click here.
